Of the 28 mAbs currently marketed in the European Union or the US, 26 are marketed in Europe and 27 are marketed in the US, with 25 marketed in both regions ([Table 1](#T1){ref-type="table"}). Catumaxomab is approved in Europe but not the US; tositumomab-I131 is marketed in the US but not Europe. Brentuximab vedotin was approved in the US in 2011 and, as of March 2012, a marketing application for the mAb is undergoing review by the European Medicines Agency.[@R1] Of the 28 mAbs that are marketed in one or the other region, 43% (12/28) are produced in Chinese hamster ovary (CHO) cells, 25% (7/28) are produced in SP2/0 cells,[@R2] 18% (5/28) are produced in NS0 cells,[@R3] and 7% (2/28) are produced in hybridomas. The remaining two products (ranibizumab, certolizumab pegol) are antigen-binding fragments (Fab) that are produced in *E. coli*. Humanized and human mAbs comprise 36% (10/28) and 32% (9/28) of the total, respectively, while 21% (6/28) are chimeric and 11% (3/28) are murine. Most (75%; 21/28) are canonical full-length mAbs. Of the 7 non-canonical mAbs, three (abciximab, ranibizumab, certolizumab pegol) are Fab, with one of these (certolizumab pegol) pegylated; two (tositumomab-I131, ibrituximab tiuxetan) are radiolabeled when administered to patients; one (brentuximab vedotin) is an antibody-drug conjugate (ADC); and one is bispecific (catumaxomab). Although 16 marketed mAbs target unique antigens, CD20 and tumor necrosis factor are each targeted by 4 mAbs, and epidermal growth factor receptor (EGFR) and vascular endothelial growth factor are each targeted by 2 mAbs. If approved, pertuzumab, which is undergoing regulatory review in Europe and the US as a treatment for breast cancer, would be one of 2 mAbs that target human epidermal growth factor receptor 2 on the market.

###### **Table 1.** Therapeutic monoclonal antibodies marketed or in review in the European Union or United States

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  International non-proprietary name (Trade name)   Manufacturing cell line   Type                                                    Target              First EU (US) approval year
  ------------------------------------------------- ------------------------- ------------------------------------------------------- ------------------- -----------------------------
  Abciximab (Reopro®)                               Sp2/0                     Chimeric IgG1κ Fab                                      GPIIb/IIIa          1995\# (1994)

  Rituximab (MabThera®, Rituxan®)                   CHO                       Chimeric IgG1κ                                          CD20                1998 (1997)

  Basiliximab (Simulect®)                           Sp2/0                     Chimeric IgG1κ                                          IL2R                1998 (1998)

  Palivizumab (Synagis®)                            NS0                       Humanized IgG1κ                                         RSV                 1999 (1998)

  Infliximab (Remicade®)                            Sp2/0                     Chimeric IgG1κ                                          TNF                 1999 (1998)

  Trastuzumab (Herceptin®)                          CHO                       Humanized IgG1κ                                         HER2                2000 (1998)

  Alemtuzumab (MabCampath, Campath-1H®)             CHO                       Humanized IgG1κ                                         CD52                2001 (2001)

  Adalimumab (Humira®)                              CHO                       Human IgG1κ                                             TNF                 2003 (2002)

  Tositumomab-I131 (Bexxar®)                        Hybridoma                 Murine IgG2aλ                                           CD20                NA (2003)

  Cetuximab (Erbitux®)                              Sp2/0                     Chimeric IgG1κ                                          EGFR                2004 (2004)

  Ibritumomab tiuxetan (Zevalin®)                   CHO                       Murine IgG1κ                                            CD20                2004 (2002)

  Omalizumab (Xolair®)                              CHO                       Humanized IgG1κ                                         IgE                 2005 (2003)

  Bevacizumab (Avastin®)                            CHO                       Humanized IgG1κ                                         VEGF                2005 (2004)

  Natalizumab (Tysabri®)                            NS0                       Humanized IgG4κ                                         α4-integrin         2006 (2004)

  Ranibizumab (Lucentis®)                           *E. coli*                 Humanized IgG1κ Fab                                     VEGF                2007 (2006)

  Panitumumab (Vectibix®)                           CHO                       Human IgG2κ                                             EGFR                2007 (2006)

  Eculizumab (Soliris®)                             NS0                       Humanized IgG2/4κ                                       C5                  2007 (2007)

  Certolizumab pegol (Cimzia®)                      *E. coli*                 Humanized IgG1κ Fab, pegylated                          TNF                 2009 (2008)

  Golimumab (Simponi®)                              Sp2/0                     Human IgG1κ                                             TNF                 2009 (2009)

  Canakinumab (Ilaris®)                             Sp2/0                     Human IgG1κ                                             IL1b                2009 (2009)

  Catumaxomab (Removab®)                            Hybrid\                   Rat IgG2b/mouse IgG2a bispecific                        EpCAM/CD3           2009 (NA)
                                                    hybridoma                                                                                             

  Ustekinumab (Stelara®)                            Sp2/0                     Human IgG1κ                                             IL12/23             2009 (2009)

  Tocilizumab (RoActemra, Actemra®)                 CHO                       Humanized IgG1κ                                         IL6R                2009 (2010)

  Ofatumumab (Arzerra®)                             NS0                       Human IgG1κ                                             CD20                2010 (2009)

  Denosumab (Prolia®)                               CHO                       Human IgG2λ                                             RANK-L              2010 (2010)

  Belimumab (Benlysta®)                             NS0                       Human IgG1κ                                             BLyS                2011 (2011)

  Raxibacumab (Pending)                             NS0\*\*                   Human IgG1κ                                             *B. anthrasis* PA   NA (In review)

  Ipilimumab (Yervoy®)                              CHO                       Human IgG1κ                                             CTLA-4              2011 (2011)

  Brentuximab vedotin (Adcentris®)                  CHO                       Chimeric IgG1κ; conjugated to monomethyl auristatin E   CD30                In review (2011)

  Pertuzumab (Pending)                              CHO                       Humanized IgG1κ                                         HER2                In review (in review)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

As of March 10, 2012. \#Country-specific approval; approved under concertation procedure \*\*Product manufactured for Phase 1 study in humans. Abbreviations: BLyS, B lymphocyte stimulator; C5, complement 5; CD, cluster of differentiation; CHO, Chinese hamster ovary; CTLA-4, cytotoxic T lymphocyte antigen 4; EGFR, epidermal growth factor receptor; EpCAM, epithelial cell adhesion molecule; Fab, antigen-binding fragment; GP glycoprotein; IL, interleukin; NA, not approved; PA, protective antigen; RANK-L, receptor activator of NFκb ligand; RSV, respiratory syncytial virus; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor. Sources: European Medicines Agency public assessment reports, United States Food and Drug Administration (drugs\@fda), the international ImMunoGeneTics information system® **(**[www.imgt.org/mAb-DB/index](http://www.imgt.org/mAb-DB/index)).

In addition to the 28 mAbs currently marketed, six mAbs were approved in at least one country of Europe or in the US, but were subsequently withdrawn or discontinued from marketing for various reasons ([Table 2](#T2){ref-type="table"}). First approved in the US in 1986, muromonab-CD3 (Orthoclone OKT3®) was a murine IgG2a used to treat acute kidney allograft rejection; however, manufacturing was discontinued in 2010 due to the availability of other treatments with similar efficacy and fewer side effects, and declining sales.[@R4]^,^[@R5] Nebacumab (Centoxin®), a human IgM, was approved in The Netherlands, Britain, Germany and France during 1991 as a treatment for Gram-negative sepsis,[@R6] but the product was subsequently withdrawn for safety, efficacy and commercial reasons.[@R7] The murine anti-epithelial cell adhesion molecule (EpCAM) edrecolomab (Panorex®) was approved in Germany in 1995 as an adjuvant treatment for colon cancer, but subsequently withdrawn because of the product's lack of efficacy.[@R8] Daclizumab was first approved in 1997 for prophylaxis of acute organ rejection in patients receiving renal transplants, but the product was voluntarily withdrawn from the market in Europe effective January 1, 2009[@R9] and discontinued for the US market because of the availability of alternative therapy and the diminished market demand.[@R10] The first ADC to be approved, gemtuzumab ozogamicin was marketed in the US for a decade before being voluntarily withdrawn in 2010. The product was approved under the accelerated approval mechanism as a treatment for acute myeloid leukemia (AML), but was withdrawn when a confirmatory clinical trial and post-approval use did not show evidence of clinical benefit in AML patients.[@R11] Efalizumab (Raptiva®) was approved in the US and Europe in 2003 and 2004, respectively, as a treatment for adults with moderate to severe plaque psoriasis, but the product was voluntarily withdrawn from both markets in 2009 because of the risk of side effects, including progressive multifocal leukoencephalopathy.[@R12]^,^[@R13]

###### **Table 2.** Therapeutic monoclonal antibodies withdrawn or discontinued from marketing in the European Union or United States

  --------------------------------------------------------------------------------------------------------------------------
  International proprietary name (Trade name)   Manufacturing\   Type              Target      First EU (US) approval year
                                                cell line                                      
  --------------------------------------------- ---------------- ----------------- ----------- -----------------------------
  Muromonab-CD3 (Orthoclone OKT3®)              Hybridoma        Murine IgG2a      CD3         1986\* (1986)

  Nebacumab (Centoxin®)                         Hybridoma        Human IgM         Endotoxin   1991\*(NA)

  Edrecolomab (Panorex®)                        Hybridoma        Murine IgG2a      EpCAM       1995\*(NA)

  Daclizumab (Zenapax®)                         NS0              Humanized IgG1κ   IL2R        1999 (1997)

  Gemtuzumab ozogamicin (Mylotarg®)             NS0              Humanized IgG4κ   CD33        NA (2000)

  Efalizumab (Raptiva®)                         CHO              Humanized IgG1κ   CD11a       2004 (2003)
  --------------------------------------------------------------------------------------------------------------------------

Note: Information current as of March 10, 2012. \*European country-specific approval. Abbreviations: CD, cluster of differentiation; CHO, Chinese hamster ovary; EpCAM, epithelial cell adhesion molecule; IL, interleukin; NA, not approved. Sources: European Medicines Agency public assessment reports, United States Food and Drug Administration (drugs\@fda), the international ImMunoGeneTics information system® **(**[www.imgt.org/mAb-DB/index](http://www.imgt.org/mAb-DB/index)).

The European Union and the US are not necessarily the first or only markets for therapeutic mAbs ([Table 3](#T3){ref-type="table"}). Nimotuzumab, a humanized mAb that targets EGFR, was developed at the Center of Molecular Immunology in Cuba. The mAb is marketed in over 20 countries, including Brazil, India and China, as a treatment for head and neck cancer or glioma, but it is not approved in the EU, US or Japan.[@R14] Mogamulizumab is a defucosylated humanized anti-CC chemokine receptor 4 (CCR4) antibody developed by Kyowa Hakko Kirin Co Ltd.[@R15] The mAb is undergoing regulatory review in Japan as a treatment for adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.

###### **Table 3.** Therapeutic monoclonal antibodies marketed or in review outside the European Union or United States

  ---------------------------------------------------------------------------------------------------------------
  International proprietary name (Trade name)   Manufacturing\   Type              Target   First approval year
                                                cell line                                   
  --------------------------------------------- ---------------- ----------------- -------- ---------------------
  Nimotuzumab (TheraCIM®, BIOMAB-EGFR®)         NS0              Humanized IgG1κ   EGFR     1999

  Mogamulizumab                                 \[Not found\]    Humanized IgG1κ   CCR4     In review in Japan
  ---------------------------------------------------------------------------------------------------------------

Note: Information current as of March 10, 2012. Abbreviations: CCR, chemokine receptor; EGFR, epidermal growth factor receptor.

The 35 marketed mAbs, most of which are canonical full-length IgG1, paved the way for the next generation of antibody-based therapeutics such as ADCs, bispecific antibodies, engineered antibodies, and antibody fragments or domains. The commercial pipeline includes \~350 mAbs now being evaluated in clinical studies around the world as treatments for many indications, including cancer, immunological disorders and infectious diseases.[@R16] The compendium of marketed therapeutic antibodies may thus be substantially larger in the future.

The author thanks Marjorie Shapiro and Mike Clark for providing detailed descriptions and references for the Sp2/0 and NS0 cell lines.
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